Introduction
============

Osteoporotic vertebral compression fracture (VCF) with refractory pain is a crippling disorder frequently resulting in severe and prolonged back pain, lengthy hospitalization, physical decline, and increased risk of death.[@b1-cia-10-635],[@b2-cia-10-635] Bed rest, opioid analgesia, and external bracing have had limited success.[@b3-cia-10-635] Percutaneous vertebral augmentation was introduced as an alternative for acute VCFs refractory to conventional medical therapy.[@b4-cia-10-635]--[@b6-cia-10-635] Although there is still debate over the effects of vertebral augmentation,[@b7-cia-10-635],[@b8-cia-10-635] it has gained acceptance as a minimally invasive method for pain relief.[@b3-cia-10-635]--[@b6-cia-10-635] There has been a significant increase in the number of vertebral augmentation procedures performed in Taiwan in the past decade.[@b9-cia-10-635]

A major concern after vertebral augmentation in patients with osteoporosis is the occurrence of new VCFs in the untreated vertebral bodies. Some authors believe that new VCFs after vertebral augmentation are caused by augmented stiffness of the treated vertebrae related to the amount of injected cement,[@b10-cia-10-635],[@b11-cia-10-635] load transfer,[@b12-cia-10-635]--[@b14-cia-10-635] and cement leakage into the adjacent vertebral disc space.[@b15-cia-10-635] It also has been proposed that these new VCFs result from the natural course of osteoporosis.[@b16-cia-10-635]--[@b19-cia-10-635] Some medications, such as corticosteroids, can disrupt skeletal architecture and result in an increase of VCFs.[@b20-cia-10-635],[@b21-cia-10-635]

New VCFs are a potential late sequela of vertebral augmentation that can bring new back pain, induce disability, and decrease patient satisfaction after the procedure. The incidence of new VCFs has been reported as 12.2%--52%.[@b18-cia-10-635],[@b19-cia-10-635],[@b22-cia-10-635] Symptomatic VCFs are common post--vertebral augmentation; subsequent vertebral augmentation procedures are usually performed for prompt pain relief.

The present study used nationwide data to estimate the incidence of subsequent vertebral augmentation for new VCFs in patients with previous vertebral augmentation. In addition, this study provides insight into risk factors for repeat vertebral augmentation in patients with previous vertebral augmentation.

Materials and methods
=====================

Database
--------

The National Health Insurance Research Database (NHIRD) included all claims data from Taiwan's National Health Insurance program. This study was exempted from full review by the Institutional Review Board because the NHIRD consisted of deidentified secondary data released to the public for research purposes. There are approximately 23 million individuals in this registry.

Study sample
------------

From January 1, 2004 to December 31, 2007, all patients undergoing vertebral augmentations were identified from the NHIRD for analysis. All subjects who suffered VCFs and underwent vertebral augmentation were individually identified and followed longitudinally until the end of the study period (December 31, 2010) or death. The follow-up for these patients was censored only at the occurrence of death or at the end of the study period.

Vertebral augmentation for VCF
------------------------------

Diagnosis at every admission was recorded in the NHIRD, according to the International Classification of Disease, 9th Revision Clinical Modification (ICD-9-CM). Any patient whose hospitalization discharge had the diagnostic code of VCF (805.xx) combined with procedures coded for vertebral augmentation (33126B, for the first vertebra, or 33127B, for any vertebra after the first level) was considered to have undergone vertebral augmentation during the hospitalization.

Subsequent vertebral augmentation for new VCF
---------------------------------------------

New VCFs resulting in subsequent procedures were defined as rehospitalization for similar diagnostic and procedure codes. These patients were identified as having undergone subsequent vertebral augmentation procedures for new VCFs.

Exclusion criteria
------------------

We excluded patients who were rehospitalized without surgical procedures codes. Often these hospitalizations may have been due to comorbidities related to VCFs. Patients who had preexisting vertebral augmentations prior to 2004 were excluded. Vertebral augmentation for metastatic spine tumor (ICD-9-CM diagnosis code 198.5) or multiple myeloma (203.0) was excluded from analysis. Patients with multiple trauma (ICD-9-CM codes 484--487) and patients who died within the date of admission were excluded.

Covariates
----------

Age, sex, and comorbidities were included for analysis. Comorbidities were identified by diagnostic codes between 3 months before and 3 months after the date of vertebral augmentation procedures. The ICD-9-CM diagnosis codes were as follows: 250.00--250.93 for diabetes mellitus (DM); 401.x−404.x for hypertension and its complications; 272.0, 272.1, 272.2, and 272.4 for hyperlipidemia; 362.34, and 430.x--438.x for cerebrovascular disease; 410.xx--414.xx for coronary heart disease; 410.x and 412.x for myocardial infarction; 440.x--447.x for peripheral vascular disease; 491.x--493.x for chronic respiratory disease; 711.xx, 712.xx, 713.x, 714.xx, 716.xx--719.xx for arthritis and other arthropathies; 580.x--588.x for chronic renal insufficiency; 290.x, 291.x, and 294.x for dementia; 369.xx for blindness and low vision; and 733.0x for osteoporosis.

Medication exposure
-------------------

Medication exposure was described in terms of proportions of patients who received at least two prescriptions from the various medication classes recommended for osteoporosis and VCF-related problems during the time period 3 months prior to vertebral augmentation and follow-up (3 months after the augmentations). The medication classes examined in this study included: calcium/vitamin D, bisphosphonates, hormone replacement therapy, selective estrogen receptor modulators, calcitonin, corticosteroids, paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants, stimulants, antipsychotics, mood stabilizers, and anxiolytics.

Statistical analysis
--------------------

Chi-square and independent *t*-tests were used to assess differences in age, sex, comorbidities, and medication exposure between patients who had had a repeat procedure and those who had not. The repeat-procedure-free rates were estimated by the Kaplan--Meier method. Stratified Cox proportional hazard regressions were performed to compare age, sex, comor-bidities, and medication exposure between repeat-procedure and repeat-procedure-free groups. All statistical analyses were conducted using the SAS statistical package (SAS System for Windows, V.9.2; SAS Institute Inc, Cary, NC, USA). A value of *P*\<0.05 was considered statistically significant.

Results
=======

Incidence and basic characteristics
-----------------------------------

From January 1, 2004 to December 31, 2007, 79,225 patients aged 45 years or older underwent vertebral augmentation procedures using the aforementioned inclusion and exclusion criteria. [Table 1](#t1-cia-10-635){ref-type="table"} shows that the number of vertebral augmentations from 2004 to 2007 in Taiwan. Among the 79,225 patients, 8,933 (11.3%) underwent a subsequent vertebral augmentation during follow-up until 2010 ([Figure 1](#f1-cia-10-635){ref-type="fig"}). The average interval to a subsequent procedure was 32.76±18.48 months. [Tables 2](#t2-cia-10-635){ref-type="table"} and [3](#t3-cia-10-635){ref-type="table"} list the baseline demographic characteristics, medication exposure, and comorbidities of the patients. [Table 4](#t4-cia-10-635){ref-type="table"} shows the results of univariate and multivariate analyses of the potential risk factors for a repeat vertebral augmentation.

Influence of age and sex on subsequent vertebral augmentation
-------------------------------------------------------------

The incidence of repeat procedure varied with age and sex in this observation. The frequency with which patients underwent a second procedure was particularly high in patients ≥80 years of age ([Table 2](#t2-cia-10-635){ref-type="table"} and [Figure 2](#f2-cia-10-635){ref-type="fig"}). In other age groups, the frequency of a second procedure was about 8.0% to 10.9%. Among 42,802 female patients, 6,110 (14.3%) had repeat vertebral augmentation. Only 2,823 of 33,600 male patients (8.4%) had a repeat procedure. Thus, female patients had a higher frequency of repeat procedures, confirmed by multivariate Cox regression analysis showing that female patients were more likely to undergo repeat vertebral augmentations than were male patients (*P*=0.008; adjusted odds ratio \[AOR\]=1.24; 95% confidence interval \[CI\]: 1.10--2.36). Old age (≥80 years) was also a predisposing factor for repeat vertebral augmentation (*P*=0.011; AOR=1.60; 95% CI: 1.31--2.08).

Comorbidities
-------------

Comorbidities in patients who underwent repeat vertebral augmentation and in those who did not are shown in [Tables 2](#t2-cia-10-635){ref-type="table"}--[4](#t4-cia-10-635){ref-type="table"}. Coronary heart disease, myocardial infarction, peripheral vascular disease, arthritis and other arthropathies, chronic respiratory disease, chronic renal insufficiency, and osteoporosis were similar between the two groups; however, DM (*P*=0.001; AOR=4.31; 95% CI: 4.05--5.88), cerebrovascular disease (*P*=0.003; AOR=4.09; 95% CI: 3.44--5.76), dementia (*P*=0.002; AOR=1.97; 95% CI: 1.69--2.33), blindness and low vision (*P*=0.002; AOR=3.72; 95% CI: 2.32--3.95), hypertension (*P*=0.009; AOR=2.58; 95% CI: 2.35--3.47), and hyperlipidemia (*P*=0.015; AOR=2.09; 95% CI: 1.67--2.22) were more common in those patients who underwent repeat vertebral augmentation.

Medication exposure
-------------------

Medication exposure in patients who underwent repeat vertebral augmentation and in those who did not is shown in [Tables 3](#t3-cia-10-635){ref-type="table"} and [4](#t4-cia-10-635){ref-type="table"}. Among the medications used to treat or prevent osteoporosis, calcium/vitamin D (*P*=0.008; AOR=2.98; 95% CI: 1.83--3.93), bisphosphonates (*P*=0.016; AOR=2.11; 95% CI: 1.26--2.61), and calcitonin (*P*=0.017; AOR=4.59; 95% CI: 3.40--5.77) were associated with patients not having repeat vertebral augmentation; however, steroids (*P*=0.009; AOR=7.28; 95% CI: 6.32--8.08), acetaminophen (*P*=0.006; AOR=3.54; 95% CI: 2.75--4.83), and NSAIDs (*P*=0.005; AOR=6.14; 95% CI: 5.08--7.41) were associated with patients having repeat vertebral augmentation. Hormone replacement therapy and selective estrogen receptor modulators did not decrease the incidence of repeat vertebral augmentation.

Discussion
==========

Vertebral augmentation is a minimally invasive method of pain relief for VCFs. There has been a significant increase in the number of vertebral augmentation procedures performed in recent years, as shown in [Table 1](#t1-cia-10-635){ref-type="table"}. Overall, 11.3% of patients who had vertebral augmentation underwent a repeat vertebral augmentation because of symptomatic VCFs during the follow-up until the end of 2010. The rate of repeat vertebral augmentation was lower than the rate of reported subsequent VCFs (12.2%--52%).[@b18-cia-10-635]--[@b20-cia-10-635] The authors did not identify subsequent VCFs because this was difficult to estimate in the database. It is likely that some patients with subsequent VCFs received conservative treatment only. Some VCFs can remain asymptomatic and are detected incidentally when a patient undergoes a radiograph for unrelated conditions;[@b2-cia-10-635] some authors believe that only one-third of patients with osteoporotic VCFs seek medical attention for back pain symptoms.[@b2-cia-10-635],[@b3-cia-10-635]

Very elderly patients (≥80 years old) were more likely to undergo a repeat vertebral augmentation (15.2%) than were those patients in other age groups (8.0%--10.9%). This observation may have been due to osteoporosis, associated comorbidities, and propensity to fall,[@b23-cia-10-635] although this current study did not demonstrate osteoporosis as a risk factor of repeat vertebral augmentation. One possible reason is that many patients did not have bone mineral density (BMD) measurement. Osteoporosis is defined by the World Health Organization (WHO) as a BMD of 2.5 standard deviations or more below the mean peak bone mass (average of young, healthy adults) as measured by dual-energy X-ray absorptiometry. Osteoporosis is likely to have been underestimated in our population-based database. Our results also demonstrate female patients were more likely to have a repeat vertebral augmentation. This is supported by two cadaver studies.[@b24-cia-10-635],[@b25-cia-10-635]

The present study demonstrates that patients with cerebrovascular disease had a higher incidence of repeat vertebral augmentation. The reasons for the association between repeat vertebral augmentation and cerebrovascular diseases are unclear. Similar to our results, patients with cerebrovascular disease have increased risk of hip fracture because of their high incidence of falls and loss of bone mass.[@b26-cia-10-635] Osteoporosis is a significant complication of cerebrovascular disease, and these patients may also have motor, sensory, and visual/perceptual deficits that predispose them to falls. Although both cerebrovascular diseases and osteoporosis are common health problems among the elderly, little attention has been paid in the literature to their correlation.[@b27-cia-10-635]

DM has been shown to be significantly associated with vertebral fractures.[@b28-cia-10-635]--[@b31-cia-10-635] Patients with DM are at greater risk of vertebral fractures, not only due to extraskeletal factors, such as predisposition to falls but also, because of alteration of bone quality and reduction of bone strength.[@b28-cia-10-635]--[@b31-cia-10-635] Recent studies have found that patients with DM had an increased risk of vertebral fractures independent of BMD or complications of DM.[@b30-cia-10-635],[@b31-cia-10-635] Therefore, these patients have a higher incidence of repeat vertebral augmentation.

Dementia and blindness and low vision were also highly associated with repeat vertebral augmentation. Their association has rarely been reported. One possible explanation is susceptibility to falls in patients with dementia and low vision.[@b32-cia-10-635]

Antiosteoporotic agents had significant efficacy in increasing lumbar spine BMD and reduction in the occurrence of any new vertebral fractures.[@b33-cia-10-635] This study demonstrates that patients who were prescribed calcium/vitamin D, bisphosphonates, and calcitonin had a lower rate of repeat vertebral augmentation; however, hormone replacement therapy and selective estrogen receptor modulators did not decrease the rate of repeat procedures in this study. The exact reason for this observation is unknown. We found that hormone replacement therapy and selective estrogen receptor modulators are used less frequently in Taiwan ([Table 2](#t2-cia-10-635){ref-type="table"}), and we surmise that these treatments could not show a significant antiosteoporotic effect in our study.

Patients on corticosteroids therapy had a higher rate of repeat vertebral augmentation. Corticosteroid therapy is associated with increased risk of vertebral fracture. Others authors also reported that patients on corticosteroid therapy at the time of their initial vertebral augmentation were almost twice as likely to have symptomatic refractures than were patients not taking corticosteroids.[@b21-cia-10-635] Loss of trabecular bone in patients on corticosteroid therapy may contribute to increased risk of VCFs. NSAIDs and acetaminophen were also associated with a higher rate of repeat procedures in the present study. Some authors have reported that NSAIDs and acetaminophen were associated with a higher fracture rate.[@b34-cia-10-635]--[@b36-cia-10-635] The increase in fracture risk may stem from changes in postural balance or an increased risk of accidents because of dizziness (a side effect of NSAIDs).[@b34-cia-10-635]

This study has some limitations. We did not investigate the incidence of VCFs because the true rate of new VCFs is difficult to estimate. Some VCFs can remain asymptomatic,[@b2-cia-10-635],[@b3-cia-10-635] and not all patients with new VCFs seek medication or undergo vertebral augmentation. Patients who undergo repeat vertebral augmentations probably have severe and prolonged back pain without response to conservative treatment. Some risk factors for refracture cannot be evaluated in the present study. It is impossible to look into the details of each operative note to clarify the cement volume, procedure style (vertebroplasty vs kyphoplasty), mechanical factors (location of the fracture, restoration of vertebral body height, and sagittal balance), surgical complications, or how many and which levels were treated in each vertebral augmentation, in such a large database study. The NHIRD data does not include details of operative notes and radiographic reports. Likewise, the degree of osteoporosis affecting each patient was not included in the data; however, the present study is the first to demonstrate the actual repeat vertebral augmentation rate in a large cohort of patients (79,225). The study provides a different viewpoint for looking at risk factors for repeat vertebral augmentation. It can be helpful in the estimation and prevention of repeat vertebral augmentation.

Conclusion
==========

A total of 11.3% of patients underwent repeat vertebral augmentation during the follow-up. Female sex, advanced age (≥80 years), cerebrovascular disease, DM, hypertension, hyperlipidemia, dementia, and low vision/blindness were characteristics associated with repeat vertebral augmentation. Calcium/vitamin D, bisphosphonates, and calcitonin were associated with a lower rate of repeat vertebral augmentation. Steroids, acetaminophen, and NSAIDs were associated with an increase in the rate of repeat vertebral augmentation. The authors identify high-risk patients, encourage the use of antiosteoporotic drugs for high-risk patients, and advocate fall prevention and avoidance of steroids and NSAIDs.
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###### 

Total 79,225 patients undergoing first vertebral augmentation

          First vertebral augmentation   Second vertebral augmentation
  ------- ------------------------------ -------------------------------
  2004    12,573                         1,759 (13.9%)
  2005    15,261                         2,080 (13.6%)
  2006    22,076                         2,351 (10.6%)
  2007    29,315                         2,743 (9.4%)
  Total   79,225                         8,933 (11.3%)

###### 

Baseline characteristics and comorbidities of 79,225 patients

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                        Underwent 2nd vertebral augmentations\   Did not undergo 2nd vertebral augmentation\   *P*-value
                                   (n=8,933)                                (n=70,292)                                    
  -------------------------------- ---------------------------------------- --------------------------------------------- --------------------------------------------------
  Age                                                                                                                     

   45--49                          53 (0.6%)                                492 (0.7%)                                    0.388

   50--54                          205 (2.3%)                               1,757 (2.5%)                                  0.261

   55--59                          447 (5.0%)                               4,499 (6.4%)                                  0.417

   60--64                          572 (6.4%)                               5,834 (8.3%)                                  0.220

   65--69                          822 (9.2%)                               9,489 (13.5%)                                 0.065

   70--74                          1,501 (16.8%)                            13,355 (19.0%)                                0.084

   75--79                          1,974 (22.1%)                            16,167 (23.0%)                                0.254

   ≥80                             3,359 (37.6%)                            18,699 (26.6%)                                0.003[\*](#tfn1-cia-10-635){ref-type="table-fn"}

  Sex, female                      6,110 (68.4%)                            36,692 (52.2%)                                0.002[\*](#tfn1-cia-10-635){ref-type="table-fn"}

  Diabetes mellitus                3,171 (35.5%)                            14,480 (20.6%)                                0.029[\*](#tfn1-cia-10-635){ref-type="table-fn"}

  Hypertension                     2,626 (29.4%)                            13,707 (19.5%)                                0.026[\*](#tfn1-cia-10-635){ref-type="table-fn"}

  Hyperlipidemia                   1,715 (19.2%)                            7,732 (11.0%)                                 0.013[\*](#tfn1-cia-10-635){ref-type="table-fn"}

  Coronary heart disease           1,635 (18.3%)                            10,825 (15.4%)                                0.670

  Myocardial infarction            304 (3.4%)                               2,038 (2.9%)                                  0.331

  Peripheral vascular disease      366 (4.1%)                               3,023 (4.3%)                                  0.129

  Cerebrovascular disease          858 (9.6%)                               2,038 (2.9%)                                  0.002[\*](#tfn1-cia-10-635){ref-type="table-fn"}

  Arthritis or other arthropathy   268 (3.0%)                               1,828 (2.6%)                                  0.475

  Chronic respiratory disease      98 (1.1%)                                633 (0.9%)                                    0.395

  Chronic renal insufficiency      366 (4.1%)                               2,671 (3.8%)                                  0.498

  Dementia                         1,027 (11.5%)                            2,038 (2.9%)                                  0.002[\*](#tfn1-cia-10-635){ref-type="table-fn"}

  Blindness or low vision          554 (6.2%)                               1,546 (2.2%)                                  0.012[\*](#tfn1-cia-10-635){ref-type="table-fn"}

  Osteoporosis                     4,556 (51.0%)                            29,944 (42.6%)                                0.056
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

*P*\<0.05.

###### 

Medication exposure in patients undergoing repeat vertebral augmentation and in those not undergoing repeat vertebral augmentation

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                Repeat vertebral augmentation\   No repeat vertebral augmentation\   *P*-value
                                           (n=8,933)                        (n=70,292)                          
  ---------------------------------------- -------------------------------- ----------------------------------- --------------------------------------------------
  Calcium/vitamin D                        2,224 (24.9%)                    26,360 (37.5%)                      0.025[\*](#tfn2-cia-10-635){ref-type="table-fn"}

  Bisphosphonates                          1,581 (17.7%)                    25,586 (36.4%)                      0.011[\*](#tfn2-cia-10-635){ref-type="table-fn"}

  Hormone replacement therapy              813 (9.1%)                       7,240 (10.3%)                       0.308

  Selective estrogen receptor modulators   1,108 (12.4%)                    9,489 (13.5%)                       0.121

  Calcitonin                               947 (10.6%)                      15,253 (21.7%)                      0.010[\*](#tfn2-cia-10-635){ref-type="table-fn"}

  Steroids                                 2,993 (33.5%)                    7,592 (10.8%)                       0.009[\*](#tfn2-cia-10-635){ref-type="table-fn"}

  Acetaminophen                            2,555 (28.6%)                    8,084 (11.5%)                       0.006[\*](#tfn2-cia-10-635){ref-type="table-fn"}

  NSAIDs                                   3,100 (34.7%)                    11,528 (16.4%)                      0.005[\*](#tfn2-cia-10-635){ref-type="table-fn"}

  Antidepressants                          759 (8.5%)                       5,412 (7.7%)                        0.363

  Stimulants                               607 (6.8%)                       4,850 (6.9%)                        0.275

  Antipsychotics                           295 (3.3%)                       1,968 (2.8%)                        0.514

  Mood stabilizers                         250 (2.8%)                       1,757 (2.5%)                        0.448

  Anxiolytics                              286 (3.2%)                       2,109 (3.0%)                        0.427
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

*P*\<0.05.

**Abbreviation:** NSAID, nonsteroidal anti-inflammatory drug.

###### 

Risk factors for undergoing repeat vertebral augmentation

                                           Univariate analysis   Multivariate analysis                                                                          
  ---------------------------------------- --------------------- ----------------------- -------------------------------------------------- ------ ------------ --------------------------------------------------
  Age (years)                              1.27                  1.19--1.50              0.030[\*](#tfn5-cia-10-635){ref-type="table-fn"}   1.60   1.31--2.08   0.011[\*](#tfn5-cia-10-635){ref-type="table-fn"}
  Sex                                      1.19                  1.03--1.87              0.019[\*](#tfn5-cia-10-635){ref-type="table-fn"}   1.24   1.10--2.36   0.008[\*](#tfn5-cia-10-635){ref-type="table-fn"}
  Diabetes mellitus                        3.75                  2.39--4.29              0.017[\*](#tfn5-cia-10-635){ref-type="table-fn"}   4.31   4.05--5.88   0.001[\*](#tfn5-cia-10-635){ref-type="table-fn"}
  Hypertension                             1.94                  1.09--2.36              0.021[\*](#tfn5-cia-10-635){ref-type="table-fn"}   2.58   2.35--3.47   0.009[\*](#tfn5-cia-10-635){ref-type="table-fn"}
  Hyperlipidemia                           1.69                  1.02--2.06              0.034[\*](#tfn5-cia-10-635){ref-type="table-fn"}   2.09   1.67--2.22   0.015[\*](#tfn5-cia-10-635){ref-type="table-fn"}
  Coronary heart disease                   0.31                  0.05--0.69              0.660                                              0.42   0.17--0.56   0.892
  Myocardial infarction                    0.81                  0.54--0.94              0.826                                              0.93   0.60--1.27   0.356
  Peripheral vascular disease              0.40                  0.25--0.79              0.115                                              0.54   0.19--0.78   0.534
  Cerebrovascular disease                  3.12                  1.27--3.97              0.026[\*](#tfn5-cia-10-635){ref-type="table-fn"}   4.09   3.44--5.76   0.003[\*](#tfn5-cia-10-635){ref-type="table-fn"}
  Arthritis and other arthropathy          0.77                  0.27--1.20              0.221                                              0.85   0.33--1.89   0.530
  Chronic respiratory disease              0.22                  0.03--0.54              0.611                                              0.49   0.38--0.67   0.397
  Chronic renal insufficiency              0.15                  0.04--0.59              0.729                                              0.24   0.13--0.40   0.408
  Dementia                                 1.77                  1.23--2.08              0.011[\*](#tfn5-cia-10-635){ref-type="table-fn"}   1.97   1.69--2.33   0.002[\*](#tfn5-cia-10-635){ref-type="table-fn"}
  Blindness and low vision                 2.09                  1.58--2.54              0.025[\*](#tfn5-cia-10-635){ref-type="table-fn"}   3.72   2.32--3.95   0.002[\*](#tfn5-cia-10-635){ref-type="table-fn"}
  Osteoporosis                             0.33                  0.18--0.86              0.253                                              0.59   0.25--0.71   0.772
  Calcium/vitamin D                        1.72                  1.18--2.11              0.020[\*](#tfn5-cia-10-635){ref-type="table-fn"}   2.98   1.83--3.93   0.008[\*](#tfn5-cia-10-635){ref-type="table-fn"}
  Bisphosphonates                          1.30                  1.05--1.80              0.034[\*](#tfn5-cia-10-635){ref-type="table-fn"}   2.11   1.26--2.61   0.016[\*](#tfn5-cia-10-635){ref-type="table-fn"}
  Hormone replacement therapy              0.28                  0.11--0.90              0.255                                              0.31   0.14--0.85   0.408
  Selective estrogen receptor modulators   0.73                  0.64--0.93              0.723                                              0.95   0.80--1.02   0.492
  Calcitonin                               2.94                  1.11--3.80              0.035[\*](#tfn5-cia-10-635){ref-type="table-fn"}   4.59   3.40--5.77   0.017[\*](#tfn5-cia-10-635){ref-type="table-fn"}
  Steroids                                 5.42                  3.63--6.48              0.015[\*](#tfn5-cia-10-635){ref-type="table-fn"}   7.28   6.32--8.08   0.009[\*](#tfn5-cia-10-635){ref-type="table-fn"}
  Acetaminophen                            2.48                  1.05--3.09              0.026[\*](#tfn5-cia-10-635){ref-type="table-fn"}   3.54   2.75--4.83   0.006[\*](#tfn5-cia-10-635){ref-type="table-fn"}
  NSAIDs                                   4.55                  3.28--7.34              0.038[\*](#tfn5-cia-10-635){ref-type="table-fn"}   6.14   5.08--7.41   0.005[\*](#tfn5-cia-10-635){ref-type="table-fn"}
  Antidepressants                          0.68                  0.53--0.93              0.947                                              0.76   0.49--0.95   0.616
  Stimulants                               0.89                  0.23--0.98              0.526                                              0.91   0.25--1.13   0.397
  Antipsychotics                           0.94                  0.71--1.41              0.911                                              0.78   0.47--0.92   0.733
  Mood stabilizers                         0.44                  0.09--0.92              0.318                                              0.53   0.42--0.81   0.630
  Anxiolytics                              0.33                  0.04--0.78              0.554                                              0.36   0.14--0.55   0.476

**Notes:** Odds ratios were adjusted for age, sex, DM, hypertension, hyperlipidemia, coronary heart disease, myocardial infarction, peripheral vascular disease, cerebrovascular disease, arthritis and other arthropathy, chronic respiratory disease, chronic renal insufficiency, dementia, blindness and low vision, osteoporosis, calcium/vitamin D, bisphosphonates, hormone replacement therapy, selective estrogen receptor modulators, calcitonin, steroids, acetaminophen, NSAIDs, antidepressants, stimulants, antipsychotics, mood stabilizers, and anxiolytics.

*P*\<0.05.

**Abbreviations:** CI, confidence interval; DM, diabetes mellitus; NSAID, nonsteroidal anti-inflammatory drug; AOR, adjusted odds ratio; OR, odds ratio.
